Clinical Trial Search

Primary: GMTs After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch. — 362; 442; 1974; 2896 geometric…

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms and Grade 3 Solicited Local Symptoms With Relationship to Vaccination - For Step 1/Cohort 1 Subjects…

Primary: Changes in Body Fat Mass. — 22.65; 23.04; 22.28; 23.17 kg — p=<0.05

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004

Primary: The Proportion of Patients Achieving Undetectable Viral Loads at Week 24. — 44; 28 percentage of participants

Primary: Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4 — -5.23; -5.24; -2.83 log10 IU/mL

Primary: Overall Survival in Patients With Low High Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression — 5.7; 6.1 months — p=<0.973

Primary: 2 Year Failure Free Survival — 20 participants

Primary: Number of Seroconverted Subjects Against the H5N1 Strain of Influenza Disease. — 72 Participants

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg

Primary: Flow-mediated Dilation of the Brachial Artery — 2.25; 3.36 percent dilation of the brachial artery — p=0.52

Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302

Primary: Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced…

Primary: Two-year Disease Free Survival. — 26.1 percentage of patients